Blackthorn.ai Company Profile

Background

Overview

Blackthorn.ai is a specialized AI software development company founded in 2021, focusing on delivering AI-driven solutions tailored for the biotech, healthcare, and life sciences sectors. The company is headquartered in San Diego, California, with additional offices in London, UK; Stuttgart, Germany; and Lviv, Ukraine.

Mission and Vision

Blackthorn.ai's mission is to empower biotech and pharmaceutical teams with custom software solutions that streamline research, automate workflows, and accelerate drug discovery. The company envisions transforming health and longevity through precision AI, aiming to bridge the gap between advanced AI technologies and practical business applications.

Primary Area of Focus

The company specializes in developing modular, research-driven AI systems for data-intensive industries, particularly biotech, healthcare, life sciences, and diagnostics. Their solutions are designed to be compliant, scalable, and capable of handling complex, messy data inherent in these sectors.

Industry Significance

Blackthorn.ai has established itself as a significant player in the AI and biotech sectors, recognized for its innovative approach to integrating AI into scientific and business processes. The company has been acknowledged as a top AI company by Clutch in 2024 and 2025, reflecting its impact and leadership in the industry.

Key Strategic Focus

Core Objectives

• Accelerate Drug Discovery: Utilize AI to streamline the drug discovery process, reducing time and costs associated with bringing new therapies to market.

• Enhance Research Capabilities: Provide AI tools that improve the efficiency and accuracy of scientific research, enabling more precise and reliable outcomes.

• Automate Workflows: Develop AI systems that automate routine tasks, allowing researchers and clinicians to focus on critical decision-making and innovation.

Specific Areas of Specialization

• AI & ML Engineering: Custom development of AI models, including large language models (LLMs) and computer vision systems.

• MLOps & Cloud Infrastructure: Establishment of production-grade AI pipelines with secure cloud infrastructure.

• Software & Product Development: Creation of AI-ready applications, either built from scratch or modernized for performance and scalability.

• Big Data & Bioinformatics: Development of multi-omics data pipelines and graph-powered analysis for life sciences.

• IT Team Extension for AI Projects: Provision of plug-and-play PhD-level AI talent to scale delivery velocity.

• Startup & R&D Acceleration: Acceleration of MVPs and research tools with flexible AI modules and lean delivery.

Key Technologies Utilized

• Machine Learning Frameworks: PyTorch, TensorFlow

• Programming Languages: Python, JavaScript

• Cloud Platforms: Azure

• Data Management Tools: Apache Kafka, Apache Spark

Primary Markets Targeted

• Biotech and Pharmaceuticals: Enhancing drug discovery and development processes.

• Healthcare Providers: Improving patient care through AI-driven diagnostics and treatment planning.

• Life Sciences Research Institutions: Facilitating complex data analysis and interpretation.

Financials and Funding

Funding History

As of April 2026, Blackthorn.ai has not publicly disclosed specific details regarding its funding history, total funds raised, or notable investors. The company operates as a privately held entity, focusing on delivering AI solutions without publicly available financial disclosures.

Utilization of Capital

While specific details on capital utilization are not publicly disclosed, it is understood that Blackthorn.ai invests in:

• Research and Development: To advance AI technologies and maintain a competitive edge.

• Infrastructure Expansion: Enhancing cloud capabilities and data management systems.

• Talent Acquisition: Recruiting top-tier AI and biotech experts to drive innovation.

Pipeline Development

Key Pipeline Candidates

Blackthorn.ai focuses on developing AI-driven solutions across various stages of the biotech pipeline, including:

• Drug Discovery: Utilizing AI to identify potential drug candidates and predict their efficacy.

• Diagnostics: Developing AI systems for early detection and accurate diagnosis of diseases.

• Personalized Medicine: Creating AI models that tailor treatment plans to individual patient profiles.

Stages of Development

The company engages in full-cycle development, from initial concept and research to deployment and scaling of AI solutions. This includes:

• Research and Feasibility Studies: Assessing the viability of AI applications in specific biotech domains.

• Prototype Development: Creating initial models and systems for proof of concept.

• Clinical Trials and Validation: Testing AI solutions in real-world settings to ensure accuracy and reliability.

• Deployment and Scaling: Implementing AI systems within operational environments and scaling them for broader use.

Target Conditions

Blackthorn.ai's AI solutions target a wide range of conditions, including:

• Oncological Diseases: Developing AI tools for cancer detection and treatment planning.

• Neurological Disorders: Creating models for early diagnosis and personalized treatment of neurological conditions.

• Cardiovascular Diseases: Utilizing AI to predict and manage heart-related health issues.

Anticipated Milestones

While specific timelines for upcoming milestones are not publicly disclosed, Blackthorn.ai is committed to:

• Continuous Innovation: Regularly releasing updated AI models and solutions.

• Regulatory Approvals: Ensuring all AI applications meet industry standards and regulatory requirements.

• Market Expansion: Broadening the adoption of AI solutions across various healthcare and biotech sectors.

Technological Platform and Innovation

Proprietary Technologies

Blackthorn.ai has developed several proprietary technologies, including:

• Modular AI Systems: Flexible AI platforms that can be customized for various biotech applications.

• Data Integration Tools: Systems designed to unify disparate data sources for comprehensive analysis.

• Predictive Modeling Algorithms: Advanced models that forecast outcomes based on complex datasets.

Significant Scientific Methods

The company employs several advanced scientific methodologies, such as:

• Multi-Omics Data Analysis: Integrating genomics, proteomics, and metabolomics data for holistic insights.

• Graph-Based Analytics: Utilizing graph theory to model complex biological networks.

• Natural Language Processing (NLP): Extracting valuable information from unstructured scientific literature.

AI-Driven Capabilities

Blackthorn.ai's AI-driven capabilities include:

• Automated Data Processing: Streamlining data cleaning and preparation for analysis.

• Real-Time Decision Support: Providing actionable insights to clinicians and researchers promptly.

• Adaptive Learning Systems: AI models that improve over time with exposure to new data.

Leadership Team

Key Executives

• Alex Gurbych, PhD – Chief Executive Officer (CEO): With over 15 years of experience in AI, Alex has led teams at Google, Shell, and Bayer. He has published in Nature and presented at NeurIPS.

• Natalya Shakhovska, DrSci, Prof. – Chief Scientific Officer (CSO): A leading scientist in AI and data systems, Natalya has over 350 scientific publications and has shaped research in NLP and big data.

• Dmytro Krasnienkov, PhD – Principal Scientist, Bioinformatics: A geneticist and bioinformatics researcher with over a decade of experience, Dmytro applies his expertise to design AI-driven pipelines for multi-omics data analysis.

• Werner Baumgartner – Director DACH & MENA: With over two decades of international experience, Werner leads business development across the DACH and MENA regions, focusing on strategic partnerships and growth acceleration.

• Serhiy Protsenko, DrSci, Prof. – Principal Data Scientist: An accomplished researcher and engineer with over a decade of experience in AI and data science, Serhiy drives the development of production-ready ML systems.

• Ivan Izonin, PhD